Table 1.
Comparisons of sex, age, H. pylori infection, and mutations of the 23S rRNA gene between subjects with and without CLR use history
| Groups | Placebo | OA | OAC | (Total) | |
| CLR use history | - | - | + | ||
| Case No. | 310 | 307 | 153 | 770 | |
| Sex ratio (M:F) | 1:1.00 | 1:1.13 | 1:0.82 | 1:1.01 | |
| Age (yrs) (Mean ± SD) | 45.3 ± 8.4 | 45.0 ± 8.4 | 45.7 ± 8.6 | 45.2 ± 8.5 | |
| H. pylori-positive rate in 2003 (%) | 13C-UBT | 90.6 (280/309) | 54.11 (166/307) | 53.3 (81/152) | 68.1 (527/768) |
| ELISA | 92.5 (283/306) | 62.11 (185/298) | 44.12 (64/145) | 71.0 (532/749) | |
| 23S rRNA | 83.9 (260/310) | 51.11 (157/307) | 26.82 (41/153) | 59.5 (458/770) | |
| Proportion of 2143G-positive H. pylori (%) | Total CLRr | 13.8 (36/260) | 10.2 (16/157) | 31.73 (13/41) | 14.2 (65/458) |
| CLRr & s | 9.6 (25/260) | 6.4 (10/157) | 14.6 (6/41) | 9.0 (41/458) | |
| Proportion of MboII-RFLP-positive H. pylori (%) | 2222CTTCA | 0.4 (1/260) | 1.9 (3/157) | 4.94 (2/41) | 1.3 (6/458) |
| 2081GAAG | 1.9 (5/260) | 1.3 (2/157) | 14.65 (4/41) | 2.4 (11/458) |
1: OA group vs. placebo group, p < 0.0000;
2: OAC group vs. OA group, p < 0.0005;
3: OAC group vs. OA group, OR = 4.09, 95%CI [1.64–10.23]; OAC group vs. placebo group, OR = 2.89, 95%CI [1.28–6.46];
4: OAC group vs. OA group, OR = 2.63, 95%CI [0.30–20.29]; OAC group vs. placebo group, OR = 13.28, 95%CI [0.91–379];
5: OAC group vs. OA group, OR = 8.38, 95%CI [1.25–68.84]; OAC group vs. placebo group, OR = 5.51, 95%CI [1.18–25.12]